Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ProPhase Labs Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
PRPH
Nasdaq
2833
http://www.prophaselabs.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ProPhase Labs Inc
ProPhase Labs Announces New $6 Million Stock Repurchase Program
- Mar 15th, 2023 12:00 pm
ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
- Mar 13th, 2023 12:00 pm
Sysco Stock Deserves a Place at Your Table
- Mar 10th, 2023 11:52 pm
ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
- Mar 7th, 2023 1:00 pm
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
- Mar 1st, 2023 1:00 pm
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
- Feb 22nd, 2023 1:00 pm
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
- Feb 16th, 2023 1:00 pm
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
- Feb 15th, 2023 1:00 pm
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
- Feb 6th, 2023 1:00 pm
While insiders own 21% of ProPhase Labs, Inc. (NASDAQ:PRPH), individual investors are its largest shareholders with 60% ownership
- Jan 19th, 2023 10:55 am
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
- Jan 5th, 2023 1:00 pm
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
- Dec 19th, 2022 1:30 pm
Implied Volatility Surging for ProPhase Labs (PRPH) Stock Options
- Dec 15th, 2022 2:12 pm
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022
- Dec 5th, 2022 1:30 pm
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
- Nov 30th, 2022 1:00 pm
ProPhase Labs Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 12th, 2022 12:43 pm
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates
- Nov 10th, 2022 2:35 pm
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
- Nov 10th, 2022 1:00 pm
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
- Nov 8th, 2022 1:00 pm
ProPhase Labs to Present at Investor Summit Group’s Q4 Conference
- Nov 8th, 2022 12:12 am
Scroll